Understanding NAD+
NAD+ is a naturally occurring coenzyme essential for cellular metabolism. It participates in energy production and several cellular processes. Research into NAD+ and related compounds explores metabolic health and aging, but these findings do not establish the benefits of injectable NAD+ use.
Full Name
Nicotinamide Adenine Dinucleotide
Classification
Cellular coenzyme; not a peptide
Primary Function
Supports cellular energy metabolism and redox reactions
Biological Role
Involved in mitochondrial function and cellular processes
Related Compounds
Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN)
Research Areas
Metabolism, aging biology and cellular energy
Important Research Distinction
NAD+, NR and NMN are different molecules. Evidence from NR or NMN supplementation studies cannot automatically establish the effectiveness of injectable NAD+.
NAD+ Dosing Patterns
The following schedules are reported clinical, community or precursor-use contexts. They are not validated personal dosing recommendations. Injectable NAD+, oral NR and oral NMN must be interpreted separately.
SC example
Per administration
Frequency
Daily total
Reported cycle
Subcutaneous (SC)
50–100 mg
2–3 times weekly
50–100 mg per administration
Community examples include escalation from 50 to 75 to 100 mg, or intensive use of 100–200 mg/day for 7–10 days.
Intramuscular (IM)
50–100 mg
1–3 times weekly
50–100 mg per administration
Community schedules vary; 1–3 administrations per week are reported.
Intravenous (IV)
250–500 mg
Weekly or fortnightly
250–500 mg per infusion
Reported loading context: 500–1,000 mg daily for 3–5 days.
Per administration
50–100 mg
Frequency
2–3 times weekly
Daily total
50–100 mg per administration
Reported cycle
Community examples include escalation from 50 to 75 to 100 mg, or intensive use of 100–200 mg/day for 7–10 days.
Per administration
50–100 mg
Frequency
1–3 times weekly
Daily total
50–100 mg per administration
Reported cycle
Community schedules vary; 1–3 administrations per week are reported.
Per administration
250–500 mg
Frequency
Weekly or fortnightly
Daily total
250–500 mg per infusion
Reported cycle
Reported loading context: 500–1,000 mg daily for 3–5 days.
Oral precursor examples are separate: NR 300–1,000 mg/day and NMN 300–900 mg/day. These are not injectable NAD+ doses.
Not a Validated Treatment Schedule
These amounts represent reported practices and study contexts, not established safe or effective regimens. Do not interpret them as instructions for self-injection or infusion.
NAD+ Safety and Tolerability
Reported adverse effects include injection-site stinging, flushing, nausea, headache and fatigue. Infusion tolerability may depend on the rate of administration. Human evidence for routine injectable use remains limited.
Reported Side Effects and Concerns
Important Safety Considerations
Product-Specific Storage Guidance
Injectable Products
Follow the exact manufacturer’s or dispensing pharmacy’s storage and handling instructions.
Premixed Solutions
Storage requirements depend on the specific formulation. Do not assume a universal refrigerated shelf life.
Oral Precursors
NR and NMN capsules have separate storage requirements from injectable NAD+ products.
Product Verification
Confirm product identity, concentration, expiry and storage instructions before use.
NAD+ Concentration Calculator
Illustrative concentration calculations for different NAD+ amounts and assumed final volumes. These are mathematical examples, not preparation or administration instructions.
Amount (mg)
Final volume (mL)
Concentration (mg/mL)
Per 1 U (mcg)
Per 10 U (mcg)
Concentration (mg/mL)
100
Concentration (mg/mL)
200
Additional source calculations: 1,000 mg / 10 mL = 100 mg/mL; 100 mg / 1 mL = 100 mg/mL; 750 mg / 7.5 mL = 100 mg/mL; 1,500 mg / 10 mL = 150 mg/mL. U refers to a U-100 syringe volume marking, where 1U = 0.01 mL. These examples do not establish sterility, compatibility, stability or suitability for injection.
What Does the Research Show?
Research includes NAD+ infusion studies and randomized trials involving oral precursors such as NR and NMN. These studies investigate different molecules and routes, so their findings cannot be treated as interchangeable evidence.
NAD+ Infusion Research
Infusion studies provide clinical context for administered NAD+, but they do not establish a universal injectable protocol or proven longevity benefit.
Oral Precursor Trials
NR and NMN randomized trials examine oral precursors. Their findings cannot automatically establish the effectiveness or safety of injectable NAD+.
Limits of Longevity Claims
An increase in circulating NAD-related measurements does not demonstrate longer lifespan, improved health outcomes or injectable clinical benefit.
Regulatory Status and Important Distinctions
Research Does Not Equal Approval
NAD+ products may be marketed in different formulations and routes. The regulatory status of a specific product depends on its formulation, intended use and jurisdiction. Research involving NR or NMN does not establish approval or clinical effectiveness for injectable NAD+.
Educational content only. NAD+ is a cellular coenzyme, not a peptide. This page does not provide medical advice or recommend self-administration. Consult a qualified healthcare professional and verify the specific product’s regulatory status and instructions.
